Results 11 to 20 of about 209,966 (285)

Regulatory Immune Cells in Idiopathic Pulmonary Fibrosis: Friends or Foes?

Frontiers in Immunology, 2021
The immune system is receiving increasing attention for interstitial lung diseases, as knowledge on its role in fibrosis development and response to therapies is expanding. Uncontrolled immune responses and unbalanced injury-inflammation-repair processes
Chiel van Geffen, Astrid Deißler, Astrid Deißler, Markus Quante, Harald Renz, Harald Renz, Dominik Hartl, Dominik Hartl, Saeed Kolahian, Saeed Kolahian, Saeed Kolahian   +10 more
doaj   +2 more sources

Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline

American Journal of Respiratory and Critical Care Medicine, 2022
Background This American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Asociación Latinoamericana de Tórax guideline updates prior idiopathic pulmonary fibrosis (IPF) guidelines and addresses the progression of ...
G. Raghu, M. Rémy-Jardin, L. Richeldi, C. Thomson, Y. Inoue, T. Johkoh, M. Kreuter, D. Lynch, T. Maher, F. Martinez, M. Molina-Molina, J. Myers, A. Nicholson, C. Ryerson, M. Strek, L. Troy, M. Wijsenbeek, M. Mammen, Tanzib Hossain, B. Bissell, D. Herman, S. Hon, F. Kheir, Y. Khor, M. Macrea, K. Antoniou, Demosthenes Bouros, I. Buendía-Roldán, F. Caro, B. Crestani, L. Ho, J. Morisset, A. Olson, A. Podolanczuk, V. Poletti, M. Selman, Thomas J. Ewing, S. Jones, Shandra L. Knight, M. Ghazipura, K. Wilson   +40 more
semanticscholar   +1 more source

Global incidence and prevalence of idiopathic pulmonary fibrosis

Respiratory Research, 2021
Background Idiopathic pulmonary fibrosis (IPF) is a progressive debilitating lung disease with considerable morbidity. Heterogeneity in epidemiologic studies means the full impact of the disease is unclear.
T. Maher, E. Bendstrup, L. Dron, J. Langley, Gerald L. Smith, J. Khalid, H. Patel, M. Kreuter   +7 more
semanticscholar   +1 more source

Impact of the new definition for pulmonary hypertension in patients with lung disease: an analysis of the United Network for Organ Sharing database

Pulmonary Circulation, 2021
The implications of the recent change in the definition of pulmonary hypertension on epidemiology and outcomes are not known. We sought to determine the percentage of patients with the two most common lung diseases that would be reclassified regarding ...
Steven D. Nathan, Scott D. Barnett, Christopher S. King, Steeve Provencher, Joan A. Barbera, Jean Pastre, Oksana A. Shlobin, Werner Seeger   +7 more
doaj   +1 more source

Clinical relevance of circulating autoantibodies in idiopathic pulmonary fibrosis; A NAt hard to break

Frontiers in Medicine, 2022
Patients with idiopathic pulmonary fibrosis are screened for circulating autoantibodies as part of the initial interstitial lung disease workup. Management of seropositive idiopathic pulmonary fibrosis is currently considered no different than that of ...
Paraskevi Kirgou, Sotirios I. Sinis, Ilias E. Dimeas, Ilias C. Papanikolaou, Konstantinos Tatsis, Athena Gogali, Konstantinos I. Gourgoulianis, Dimitrios P. Bogdanos, Zoe Daniil   +8 more
doaj   +1 more source

Idiopathic Pulmonary Fibrosis: An Update on Pathogenesis

Frontiers in Pharmacology, 2022
Idiopathic pulmonary fibrosis (IPF) is a progressive, lethal fibrotic lung disease that occurs primarily in middle-aged and elderly adults. It is a major cause of morbidity and mortality. With an increase in life expectancy, the economic burden of IPF is
Qian Mei, Zhe Liu, He-Ning Zuo, Zhenhua Yang, Jing Qu   +4 more
semanticscholar   +1 more source

Radiological findings based comparison of functional status in patients who have post-covid lung injury or idiopathic pulmonary fibrosis

BMC Pulmonary Medicine, 2023
Background Following COVID-19 infection, some patients acquired lung injury and fibrosis. Idiopathic pulmonary fibrosis is characterized by lung fibrosis.
Deniz Kızılırmak, Seçil Sarı, Fatma Can, Yavuz Havlucu   +3 more
doaj   +1 more source

The Role of DNA Damage and Repair in Idiopathic Pulmonary Fibrosis

Antioxidants, 2022
The mortality rate of idiopathic pulmonary fibrosis (IPF) increases yearly due to ineffective treatment. Given that the lung is exposed to the external environment, it is likely that oxidative stress, especially the stimulation of DNA, would be of ...
Jiahui Zhu, Lexin Liu, Xiaodi Ma, Xinyu Cao, Yu Chen, Xiangping Qu, Ming Ji, Huijun Liu, Chi Liu, Xiaoqun Qin, Yang Xiang   +10 more
doaj   +1 more source

Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis

Drugs, 2023
Idiopathic pulmonary fibrosis (IPF) remains a disease with poor survival. The pathogenesis is complex and encompasses multiple molecular pathways. The first-generation antifibrotics pirfenidone and nintedanib, approved more than 10 years ago, have been ...
F. Bonella, Paolo Spagnolo, Chris Ryerson   +2 more
semanticscholar   +1 more source

Idiopathic pulmonary fibrosis: Current and future treatment

Clinical Respiratory Journal, 2022
Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic lung disease characterized by dry cough, fatigue, and progressive exertional dyspnea. Lung parenchyma and architecture is destroyed, compliance is lost, and gas exchange is compromised in this ...
Daniel S. Glass, D. Grossfeld, Heather A. Renna, Priya Agarwala, P. Spiegler, J. Deleon, A. Reiss   +6 more
semanticscholar   +1 more source